Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2015, Pages 691-697

  Christensen, Mette Marie Hougaard ^a   Højlund, Kurt ^b   Hother Nielsen, Ole ^b   Stage, Tore Bjerregaard ^a   Damkier, Per ^a,b   Beck Nielsen, Henning ^b   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Healthy volunteers; Metformin; OCT1; Pharmacogenetics; Reduced function alleles

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; ORGANIC CATION TRANSPORTER 1;

ADULT; ALLELE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; ALLELES; CROSS-OVER STUDIES; FEMALE; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; ORGANIC CATION TRANSPORTER 1; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84953356353     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1853-8     Document Type: Article

References (45)

1. UKPDS Group 1998 (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865
2. Hundal RS, Krssak M, Dufour S et al (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069
3. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3):607-614
4. El-Mir MY, Nogueira V, Fontaine E et al (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223-228
5. Stephenne X, Foretz M, Taleux N et al (2011) Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 54:3101-3110. doi: 10.1007/s00125-011-2311-5
6. Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542-546. doi: 10.1038/nature13270
7. Koepsell H, Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666-676
8. Pentikainen PJ, Neuvonen PJ, Penttila A (1979) Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 16(3):195-202
9. Zhou M, Xia L, Wang J (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35:1956-1962
10. Muller J, Lips KS, Metzner L et al (2005) Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70:1851-1860
11. Graham GG, Punt J, Arora M et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81-98. doi: 10.2165/11534750-000000000-00000
12. Koepsell H (2004) Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 25:375-381
13. Dresser MJ, Zhang L, Giacomini KM (1999) Molecular and functional characteristics of cloned human organic cation transporters. Pharm Biotechnol 12:441-469
14. Becker ML, Visser LE, van Schaik RH et al (2009) Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 9:242-247
15. Shikata E, Yamamoto R, Takane H et al (2007) Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 52:117-122
16. Shu Y, Sheardown SA, Brown C et al (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422-1431
17. Shu Y, Brown C, Castro RA et al (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273-280
18. Tzvetkov MV, Vormfelde SV, Balen D et al (2009) The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 86:299-306
19. Christensen MMH, Brasch-Andersen C, Green H et al (2011) The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 21:837-850. doi: 10.1097/FPC.0b013e32834c0010
20. Tarasova L, Kalnina I, Geldnere K et al (2012) Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics 22:659-666. doi: 10.1097/FPC.0b013e3283561666
21. Meyer Zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB (2010) Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Ren Physiol 298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009
22. Chen Y, Li S, Brown C et al (2009) Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19:497-504
23. Song IS, Shin HJ, Shim EJ et al (2008) Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 84:559-562
24. Wang ZJ, Yin OQ, Tomlinson B, Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637-645
25. Christensen MMH, Pedersen RS, Stage TB et al (2013) A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics 23:526-534. doi: 10.1097/FPC.0b013e328364a57d
26. Stocker SL, Morrissey KM, Yee SW et al (2013) The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 93:186-194. doi: 10.1038/clpt.2012.210
27. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2009) Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genom 20(1):38-44. doi: 10.1097/FPC.0b013e328333bb11
28. Goswami S, Yee SW, Stocker S et al (2014) Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 96:370-379. doi: 10.1038/clpt.2014.109
29. Stage TB, Pedersen RS, Damkier P et al (2014) Intake of St John's wort improves the glucose tolerance in healthy subjects that ingest metformin compared to metformin alone. Br J Clin Pharmacol. doi: 10.1111/bcp.12510
30. Pedersen RS, Christensen MM, Brosen K (2012) Linkage disequilibrium between the CYP2C19∗17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. Eur J Clin Pharmacol 68:1463-1464. doi: 10.1007/s00228-012-1272-z
31. Nielsen F, Christensen MM, Brosen K (2013) Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study. Ther Drug Monit. doi: 10.1097/FTD.0b013e3182a4598a
32. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989. doi: 10.1086/319501
33. Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76:449-462. doi: 10.1086/428594
34. Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247-254
35. Thomas MC, Tikellis C, Burns WC et al (2003) Reduced tubular cation transport in diabetes: prevented by ACE inhibition. Kidney Int 63:2152-2161. doi: 10.1046/j.1523-1755.2003.00006.x
36. Habu Y, Yano I, Takeuchi A et al (2003) Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. Biochem Pharmacol 66:1107-1114
37. Denk GU, Soroka CJ, Mennone A et al (2004) Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatol Baltim Md 39:1382-1389. doi: 10.1002/hep.20176
38. Nies AT, Koepsell H, Winter S et al (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227-1240. doi: 10.1002/hep.23103
39. Savic RM, Yee S, Giacomini KM (2011) Effect of genetic variation in the organic cation transporter 1 and 2 on metformin pharmacokinetics: nonlinear mixed-effects analysis. Clin Pharmacol Ther 89(supplement 1):5
40. Stage TB, Damkier P, Pedersen RS et al (2015) A twin study of the trough plasma steady-state concentration of metformin. Pharmacogenet Genomics. doi: 10.1097/FPC.0000000000000133
41. Zhou K, Donnelly L, Yang J et al (2014) Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2:481-487. doi: 10.1016/S2213-8587(14)70050-6
42. Kajiwara M, Terada T, Asaka J et al (2007) Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1. Am J Physiol Ren Physiol 293:F1564-F1570
43. Choi JH, Yee SW, Ramirez AH et al (2011) A common 5′-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 90:674-684. doi: 10.1038/clpt.2011.165
44. Nie W, Sweetser S, Rinella M, Green RM (2005) Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha and -gamma. Am J Physiol Gastrointest Liver Physiol 288:G207-G212. doi: 10.1152/ajpgi.00057.2004
45. Saborowski M, Kullak-Ublick GA, Eloranta JJ (2006) The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4α. J Pharmacol Exp Ther 317:778-785. doi: 10.1124/jpet.105.099929